Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Québec, H3A 2B4, Canada.
F1000Res. 2024 Sep 5;13:781. doi: 10.12688/f1000research.153243.2. eCollection 2024.
Casein kinase II subunit alpha (CSNK2A1), a serine/threonine kinase, phosphorylates multiple protein substrates and is involved in diverse cellular and biological processes. Implicated in various human diseases, high-performing antibodies would help evaluate its potential as a therapeutic target and benefit the scientific community. In this study, we have characterized ten CSNK2A1 commercial antibodies for western blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. These studies are part of a larger, collaborative initiative seeking to address antibody reproducibility issues by characterizing commercially available antibodies for human proteins and publishing the results openly as a resource for the scientific community. While use of antibodies and protocols vary between laboratories, we encourage readers to use this report as a guide to select the most appropriate antibodies for their specific needs.
酪蛋白激酶 II 亚单位 α(CSNK2A1)是一种丝氨酸/苏氨酸激酶,可磷酸化多种蛋白质底物,参与多种细胞和生物过程。该蛋白与多种人类疾病相关,高特异性的抗体将有助于评估其作为治疗靶点的潜力,并使科学界受益。在这项研究中,我们使用基于比较敲除细胞系和同源亲本对照中读出值的标准化实验方案,对 CSNK2A1 的十种商业抗体进行了 Western blot、免疫沉淀和免疫荧光检测。这些研究是一个更大的合作计划的一部分,该计划旨在通过对人类蛋白的商业抗体进行特征描述,并将结果公开作为科学界的资源,来解决抗体重现性问题。虽然不同实验室使用的抗体和方案有所不同,但我们鼓励读者将本报告用作指南,根据其特定需求选择最合适的抗体。